Chatbots for dementia still in their infancy, tech researchers find … What to know about new Alzheimer’s drug Aduhelm, from scientist who led the trials … Advocacy group urges OIG to investigate FDA’s approval of new Alzheimer’s drug … First patient receives controversial Biogen Alzheimer’s drug at hospital … LTC care needs will double by 2065 … FDA approves Novartis’ drug for aggressive prostate cancer following positive trial results
Clinicians’ responses to the controversial approval of Aduhelm range between excitement and disapproval, with questions abounding on how to advise patients on treatment and the cost to patients and Medicare.
